News

Article

Canada OKs Samsung BioLogics’ mAb Drug Substance Plant

The contract development and manufacturing company has received an additional approval from Health Canada to manufacture monoclonal antibody drug substance at its first plant in Icheon, South Korea.

Samsung BioLogics, a contract development and manufacturing organization (CDMO) announced on June 21, 2018 that Health Canada has licensed its first plant in Icheon, South Korea, to manufacture a monoclonal antibody drug substance.

Health Canada’s approval marks the second drug product approval and third global approval for Samsung BioLogics, following approvals from FDA, European Medicines Agency, and Pharmaceuticals and Medical Devices Agency in Japan. Samsung BioLogics has received a total of 14 global manufacturing approvals for 14 biologics products. The company expects to reach a total of 30 approvals from global regulatory agencies within 2018.

“Samsung BioLogics has grown rapidly during the last seven years with 14 global regulatory agency approvals and 362,000 liters biologics manufacturing capacity,” said TH Kim, CEO and president of Samsung BioLogics, in a company press release. “We will change the paradigm of the bio industry with innovation and ultimately benefit the patients by providing the biologics drugs in a timely manner at lower cost.”

Source: Samsung BioLogics

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Related Videos
A global supply chain map, visualizing the complex network of transportation routes and distribution centers | Image Credit: © venusvi - stock.adobe.com
Shortcut from point A to point B | Image Credit: © Olivier Le Moal - stock.adobe.com
Behind the Headlines, Episode 21: Waters-BD Merger, Merck’s $10B Bet, and Biotech’s Investment Frontiers
Wooden blocks spelling TARIFFS are placed on a map of North America, specifically over the United States and Mexico | Image Credit: © Rokas - stock.adobe.com
Jason Waite, International Trade Expert, Alston & Bird
Simona Guidi, Associate Director, ProPharma
Tore Bergsteiner
Behind the Headlines, Episode 20: CAR-T Milestones, Abbvie and Eli Lilly M&A Moves, and More